Exogems is a Swiss biotech company utilizing the Lipogems® device for the closed-loop processing and transfer of autologous adipose tissue, which contains mesenchymal stem cells that enhance tissue regeneration. The company focuses on producing highly efficacious exosomes to address inflammation, infection, and cancer through a scalable and cost-effective biopharmaceutical manufacturing process.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for producing therapeutic exosomes often lack scalability and cost-effectiveness, hindering widespread access to exosome-based therapies for inflammation, infection, and cancer. Existing exosome production techniques may also yield inconsistent exosome quality and efficacy.
Solution
Exogems leverages the Lipogems® device, a closed-loop system for processing autologous adipose tissue, to produce highly efficacious exosomes. The Lipogems® device isolates mesenchymal stem cells (MSCs) from adipose tissue, which then secrete exosomes with regenerative properties. By combining the Lipogems® technology with scalable biopharmaceutical manufacturing processes, Exogems aims to provide a consistent and cost-effective source of therapeutic exosomes for addressing inflammation and promoting tissue regeneration.
Target Audience
The primary target audience includes researchers and pharmaceutical companies developing exosome-based therapies for inflammation, infection, cancer, and regenerative medicine applications.
Features
- Utilizes the Lipogems® device for closed-loop processing of autologous adipose tissue.
- Employs MSCs contained within the fat tissue for exosome production.
- Focuses on producing exosomes with high efficacy for regenerative medicine.
- Aims for scalable and cost-effective biopharmaceutical manufacturing of exosomes.